BioScience Health Innovations Changes Fiscal Year End

TL;DR

BioScience Health Innovations (formerly Nowtransit) is changing its fiscal year end to Dec 31st, effective March 14, 2025.

AI Summary

BioScience Health Innovations, Inc. filed an 8-K on March 17, 2025, reporting a change in its fiscal year end to December 31st, effective March 14, 2025. The company, formerly known as Nowtransit Inc., is incorporated in Nevada and its principal executive offices are located at 2722 S West Temple, Salt Lake City, UT 84115.

Why It Matters

This filing indicates a change in the company's financial reporting calendar, which could impact the timing of future financial disclosures and investor analysis.

Risk Assessment

Risk Level: low — The filing is a routine administrative change regarding the company's fiscal year end and does not involve significant financial or operational events.

Key Players & Entities

• BioScience Health Innovations, Inc. (company) — Registrant
• March 14, 2025 (date) — Date of earliest event reported
• March 17, 2025 (date) — Date of Report
• Nowtransit Inc. (company) — Former company name
• 2722 S West Temple (address) — Principal executive offices
• Salt Lake City, UT 84115 (address) — Principal executive offices
• Nevada (jurisdiction) — State of incorporation
• December 31 (date) — New Fiscal Year End

FAQ

From the Filing

0001185185-25-000186.txt : 20250317 0001185185-25-000186.hdr.sgml : 20250317 20250317071700 ACCESSION NUMBER: 0001185185-25-000186 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250314 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year FILED AS OF DATE: 20250317 DATE AS OF CHANGE: 20250317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioScience Health Innovations, Inc. CENTRAL INDEX KEY: 0001784440 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] ORGANIZATION NAME: 06 Technology IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-234487 FILM NUMBER: 25742335 BUSINESS ADDRESS: STREET 1: 2722 S WEST TEMPLE CITY: SALT LAKE CITY STATE: UT ZIP: 84115 BUSINESS PHONE: 801-949-0791 MAIL ADDRESS: STREET 1: 2722 S WEST TEMPLE CITY: SALT LAKE CITY STATE: UT ZIP: 84115 FORMER COMPANY: FORMER CONFORMED NAME: Nowtransit Inc DATE OF NAME CHANGE: 20190802 8-K 1 notr8k031425.htm FORM 8-K false --12-31 0001784440 0001784440 2025-03-14 2025-03-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): March 14, 2025   BioScience Health Innovations, Inc. (Exact name of the registrant as specified in its charter)   Nevada   333-234487   98-1498782 (State or other jurisdiction of   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   2722 S West Temple Salt Lake City , UT 84115 (Address of principal executive offices) (Zip code)   Registrant’s telephone number, including area code: ( 801 ) 949-0791   NOWTRANSIT INC. (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol(s)   Name of exchange on which registered N/A   N/A   N/A   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒ .             Item 5.03 Amendments to Articles of Incorporation or Bylaws   On February 21, 2025, Nowtransit, Inc. (the “Company”) amended its Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a change of the Company’s name from “Nowtransit, Inc.” to “BioScience Health Innovations, Inc.” (the “Name Change”). The Name Change became effective on February 21, 2025.   The Board of Directors of the